45 citations
,
January 2012 in “The Journal of Steroid Biochemistry and Molecular Biology” Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
30 citations
,
June 2010 in “Endocrine Related Cancer” SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
July 2025 in “Saudi Journal of Medicine and Public Health” 5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
5 citations
,
December 2022 in “Viruses” Antiandrogens may help prevent or treat COVID-19 by blocking virus entry into cells.
51 citations
,
June 1970 in “British journal of dermatology/British journal of dermatology, Supplement” Antiandrogens may help treat conditions like excessive hair growth, prostate tumors, male baldness, and acne by blocking male hormone effects.
August 2019 in “Carolina Digital Repository (University of North Carolina at Chapel Hill)” DHT enhances androgen receptor activity more than testosterone, and MAGE-11 influences this activity through specific interactions.
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
January 2009 in “DOAJ (DOAJ: Directory of Open Access Journals)” Serenoa repens is not proven effective for hair loss and may delay prostate cancer detection.
January 2026 in “Nature Reviews Urology” 28 citations
,
January 2009 in “Journal of Cutaneous and Aesthetic Surgery” Serenoa repens is not proven effective for hair loss and may delay prostate cancer detection.
Neurosteroids help control dopamine responses in the brain.
5α-reductase inhibitors help treat prostate enlargement and hair loss but may cause side effects, requiring careful use.
February 2026 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
14 citations
,
April 2024 in “The Journal of Steroid Biochemistry and Molecular Biology” 5α-reductases increase epitestosterone's effect on androgen receptors.
82 citations
,
February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
April 2023 in “Medicina Clínica (english Edition)”
24 citations
,
April 2014 in “Oncotarget” Minoxidil can reduce functions related to androgen receptors.
38 citations
,
January 2005 in “PubMed” Dutasteride effectively treats enlarged prostate with manageable side effects.
1 citations
,
January 2015 in “Hair therapy & transplantation” New drug dutasteride effectively treats hair loss, but use cautiously due to potential sexual side effects.
20 citations
,
January 2003 in “Chemical and Pharmaceutical Bulletin” The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.
November 2022 in “Molecular Pharmaceutics” cp-asiAR may effectively treat androgenetic alopecia by promoting hair growth and reducing androgen receptor activity.
25 citations
,
June 2002 in “Steroids” 4-azasteroids, including finasteride, can inhibit 5α-reductase, helping treat conditions like enlarged prostate and hair loss.
February 2009 in “RePub (Erasmus University Rotterdam)” Androgen receptor activity is influenced by hormones, co-factors, modifications, and mutations.
25 citations
,
November 2005 in “PubMed” Finasteride changes androgen receptor location in rat epididymis without altering tissue structure.
June 2023 in “Sri Lanka Journal of Menopause” 23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
October 2022 in “Frontiers in Bioengineering and Biotechnology” Bioengineered nanoparticles can effectively treat hair loss by targeting specific enzymes and receptors.
February 2026 in “Revista Eletrônica Polidisciplinar Voos.” A balanced approach using dutasteride and Serenoa repens can improve hair transplant success by protecting follicles and minimizing side effects.